key: cord-0312891-wqivdf2k authors: Zadeh, Vahid Rajabali; Urata, Shuzo; Afowowe, Tosin Oladipo; Yasuda, Jiro title: Potential and action mechanism of favipiravir as an antiviral against Junin virus date: 2021-12-15 journal: bioRxiv DOI: 10.1101/2021.12.14.472716 sha: 2b1dc6af9f22c6ce21069523dc4fe85cc0555ea7 doc_id: 312891 cord_uid: wqivdf2k Favipiravir is a nucleoside analogue that inhibits the replication and transcription of a broad spectrum of RNA viruses, including pathogenic arenaviruses. In this study, we isolated a favipiravir-resistant mutant of Junin virus (JUNV), which is the causative agent of Argentine hemorrhagic fever, and analyzed the antiviral mechanism of favipiravir against JUNV. Two amino acid substitutions, N462D in the RNA-dependent RNA polymerase (RdRp) and A168T in the glycoprotein precursor GPC, were identified in the mutant. GPC-A168T substitution enhanced the efficiency of JUNV internalization, which explains the robust replication kinetics of the mutant in the virus growth analysis. Although RdRp-N462D substitution did not affect polymerase activity levels in a minigenome system, comparisons of RdRp error frequencies showed that the virus with RdRp-D462 possessed a significantly higher fidelity. We also provided experimental evidence for the first time that favipiravir inhibited JUNV through the accumulation of transition mutations, confirming its role as a purine analogue against arenaviruses. Moreover, we showed that treatment with a combination of favipiravir and either ribavirin or remdesivir inhibited JUNV replication in a synergistic manner, blocking the generation of the drug-resistant mutant. Our findings provide new insights for the clinical management and treatment of Argentine hemorrhagic fever. hemorrhagic fever, and analyzed the antiviral mechanism of favipiravir against JUNV. Two Ebola virus showed lack of efficacy of favipiravir treatment in reducing the viral load reduction and improving survival of the affected subjects (Madelain et al., 2017) . Prior to the discovery 62 of favipiravir, ribavirin was the only available antiviral drug effective against JUNV 63 (Weissenbacher et al., 1986) . However, several concerns over safety and efficacy are linked 64 with the use of ribavirin, limiting its clinical use (Enria et al., 2008) . Several pre-clinical studies 65 investigated the inhibitory effect of antiviral drugs in JUNV infections (Gowen et Quantification of viral titers at 48 hours post infection (hpi), showed favipiravir IC50 to be 4.9 103 µM with 95% confidence interval (CI) of 4.5 µM to 5.4 µM. This value is comparable with 104 that of a previous study reporting favipiravir IC50 for JUNV in Vero cells (Gowen et al., 2007) . The cytotoxicity assay showed that favipiravir lacked toxic effects on cell viability at the 106 specified concentrations (Fig. S1) . We selected 5 µM of favipiravir as an optimal selective 107 pressure. First, the cells were infected with the JUNV Candid #1 strain (MOI: 0.01). After 108 adsorption, medium containing either favipiravir or DMSO was added, and cells were then 109 incubated. Additional infection control using fresh virus stock (no passage control) in the 110 absence of favipiravir/DMSO was used to monitor the accumulation of defective interfering 111 particles (data not shown) (Ziegler and Botten, 2020) . Viral titers were measured using plaque 112 assays after every passage. On the first two initial passages, P0 and P1, JUNV titers showed an 113 81.7-and 105-fold reduction, respectively (Fig. 1A) . To increase the selective pressure, 114 favipiravir concentration was increased to 20 µM (approximately IC90) for subsequent passages. The increase of favipiravir concentration was associated with a reduction in titer similar to that 116 detected using 5-µM favipiravir, indicating that a resistant population was beginning to emerge. As shown in Fig. 1A , at passage 11 (P11), viral titers were similar to those of no-drug controls, 118 suggesting that a dominant proportion of the viral population was resistant to favipiravir. All four clones showed the same mutations as the P0 parental virus. Three nucleotide 131 substitutions, two in the RdRp coding region (1384 A to G, 3669 A to G) and one in the GPC 132 coding region (502 G to A), were identified in P11 mutants (Fig. 2) . In the RdRp region, the A 133 to G substitution at 3669 generated a synonymous mutation, whereas the A to G substitution at #1-res were incubated and culture supernatants were collected at 8, 12, 24, and 28 hpi Viral 143 titers in the culture supernatants were determined by plaque assay. Efficient replication of Candid #1-res was observed at 8 hpi, which was much earlier than that of parental Candid #1 145 (Fig. 3) . However, there was no significant difference between the titers of both viruses at 28 146 hpi, indicating that Candid #1-res exhibited the rapid growth. No differences in plaque 147 morphologies were observed (data not shown). In contrast, specific infectivity of Candid #1-res virus was only slightly affected from 1.009 to 190 0.80 log10 PFU per mL/log10 RNA copies per mL, when exposed to 2-µM and 64-µM 191 favipiravir respectively. The significant reduction in specific infectivity of Candid #1 compared 192 to that of the Candid #1-res virus (P < 0.0001, two-way ANOVA test) suggests that the resistant 193 mutant is less susceptible to the mutagenic effect of favipiravir. Notably, we did not observe 194 any difference in viral RNA copy numbers between Candid #1 and Candid #1-res variants 195 across any concentration (up to 64 µM) of favipiravir treatment (data not shown). Taken 196 together, these data indicate that the lower susceptibility of Candid #1-res virus to favipiravir 197 is mediated by its higher replication fidelity. rates. We observed that N462D substitution had no significant effect on RNA polymerase 230 activity (Fig. 7C) . To examine the sensitivity of RdRp-D462 to favipiravir, the activity of both 231 polymerases exposed to different concentrations of the drug using a minigenome system was although RdRp-D462 showed a slightly increased resistance to favipiravir compared with that 235 of RdRp-N462 (Fig. 7D) . No cytotoxicity was observed in this assay (Fig. 7E) . Quantification 236 of the luciferase mRNA showed that high concentrations of favipiravir (≥200 µM) act as a 237 chain terminator, and reflected the reduction of luciferase signal in the MG assay (Fig. 7F) . In this study, we attempted to understand the mechanism of antiviral action of (Fig. 4) . The leading 272 hypothesis on the mechanism of the favipiravir resistance observed in this study is that the 273 during replication and transcription, resulting in lower favipiravir incorporation, as described 275 for other mutagen-resistant RNA viruses (Cheung et al., 2014; Pfeiffer and Kirkegaard, 2003) . 276 Further analysis of binding affinities will clarify the precise mechanism of D462 resistance to 277 favipiravir. Notably, the higher fidelity of Candid #1 mutant virus correlated with resistance to 278 favipiravir, and the virus remained susceptible to higher concentrations of the drug, indicating 279 that RdRp-D462 does not tolerate the chain termination activity of favipiravir, as was 280 demonstrated in this study through the MG system (Fig. 7D and F) . Accordingly, the Candid The other mutation (A168T) identified in this study was found to be within the GP1 293 subunit of the glycoprotein complex (GPC). Arenavirus GPC is a precursor protein that forms 294 a trimer of stable signal peptides, GP1 and GP2 subunits, upon maturation by cellular enzymes. During virus entry, GP1 and GP2 are responsible for the recognition of receptors and the fusion 296 with endosome membranes, respectively (Urata and Yasuda, 2012). While A168T substitution 297 led to more efficient viral entry (Fig. 6) , no impact on attachment of pseudotype viral particles 298 to the target cells was observed (data not shown), suggesting that the functional importance of 299 the A168T substitution is on the post-attachment step of JUNV virus entry. Consistent with 300 this, growth kinetics of the Candid #1-res virus represented more robust replication at earlier 301 time points (Fig. 3) . In recent years, a novel mechanism of drug resistance mediated by an Here, we experimentally demonstrated that the potency of favipiravir could be 311 significantly enhanced against JUNV if used in combination with ribavirin or remdesivir (Fig. 312 8) . Furthermore, we showed that it was difficult to isolate JUNV variants that were resistant to 313 the combination treatment (Fig. S4) . These findings suggest the potential of combination 314 therapies for favipiravir with ribavirin or remdesivir. 315 In conclusion, we described the isolation of a high replication fidelity variant of 316 arenavirus with reduced susceptibility to favipiravir. More importantly, we provide 317 experimental evidence that hyper-mutagenesis is the primary mechanism of favipiravir action (Table S1) RNA was extracted from culture supernatants and used to amplify a part of the NP gene using 399 primer number five described in Table S1 , with the high-fidelity One Step RT-PCR Kit (Takara was then serially diluted using DEPC-treated water to obtain a standard curve ranging from 463 10 2 -10 13 copies/mL. To quantify the nano-luciferase mRNA extracted from the minigenome 464 assay, relative qPCR was performed using GAPDH expression as a control, as previously First 535 evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa Viral Hepat Favipiravir elicits antiviral mutagenesis during virus 538 replication in vivo Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir Extinction of Zika Virus and Usutu 543 Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic 544 Drugs Hemorrhagic fever viruses as biological weapons: medical and public 550 health management A structural and primary sequence comparison of the viral RNA-dependent RNA 552 polymerases Domain 554 Structure of Lassa Virus L Ebola virus entry requires the cholesterol transporter Niemann-559 Pick C1 Determining Ribavirin's mechanism of action against Lassa virus infection Generation and characterization of influenza A viruses with 565 altered polymerase fidelity Favipiravir as a potential countermeasure against neglected 567 and emerging RNA viruses Mutations in the chikungunya virus non-structural 572 proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral Arenavirus reverse genetics: New approaches for the 575 investigation of arenavirus biology and development of antiviral strategies. Virology, Special 576 Reviews Issue 578 Rescue from Cloned cDNAs and In Vivo Characterization of Recombinant Pathogenic Romero 579 and Live-Attenuated Candid #1 Strains of Junin Virus, the Causative Agent of Argentine 580 Hemorrhagic Fever Disease Special Issue: Treatment of highly pathogenic RNA viral infections 78 T-705 induces lethal mutagenesis in Ebola and Marburg 586 populations in macaques Mechanism of action of interferon and ribavirin in treatment of 589 hepatitis C Mechanism of action of T-705 against influenza virus Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-595 Generation Sequencing The mechanism of resistance to favipiravir in influenza Second-generation live-attenuated Candid#1 vaccine virus resists 602 reversion and protects against lethal Junín virus infection in guinea pigs Favipiravir (T-705) Inhibits Junín Virus Infection 606 and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever Enhanced protection against experimental Junin virus infection through the 610 use of a modified favipiravir loading dose strategy Vitro and In Vivo Activities of T-705 against Arenavirus and 614 Bunyavirus Infections Arenavirus Quasispecies and Their 617 Biological Implications Antiviral efficacy of 621 favipiravir against Ebola virus: A translational study in cynomolgus macaques SynergyFinder 2.0: visual analytics of multi-drug 624 combination synergies 2021. iPSC screening for drug repurposing identifies 628 anti-RNA virus agents modulating host cell susceptibility Effect of ribavirin and tributylribavirin 631 on argentine hemorrhagic fever (Junin virus) in guinea pigs Different 634 effects of two mutations on the infectivity of Ebola virus glycoprotein in nine mammalian 635 species Lassa viral dynamics in non-human primates 637 treated with favipiravir or ribavirin Remdesivir 642 targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases Favipiravir Pharmacokinetics in 646 Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses Ribavirin prophylaxis and therapy for 649 experimental argentine hemorrhagic fever Safety and immunogenicity of 652 a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques T-705 (Favipiravir) Inhibition 656 of Arenavirus Replication in Cell Culture Effective Oral Favipiravir (T-705) Therapy Initiated after the Onset of Clinical Disease in a 660 Model of Arenavirus Hemorrhagic Fever Life cycle 663 synchronization is a viral drug resistance mechanism Generation of influenza A viruses entirely 667 from cloned cDNAs NIAID Emerging Infectious Diseases/Pathogens | NIH: National Institute of Allergy and Infectious 670 Diseases Effective Lethal Mutagenesis of Influenza Virus by Three Nucleoside 673 Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-678 central Nigeria Structural insight into arenavirus replication machinery Increased Fidelity Reduces Poliovirus Fitness and Virulence under 684 Selective Pressure in Mice A single mutation in poliovirus RNA-dependent RNA polymerase 687 confers resistance to mutagenic nucleotide analogs via increased fidelity Use of 691 Favipiravir to Treat Lassa Virus Infection in Macaques Ribavirin-Resistant Mutants of Human Enterovirus 71 694 Express a High Replication Fidelity Phenotype during Growth in Cell Culture Kinetics of the viral cycle influence pharmacodynamics of 696 antiretroviral therapy Watching Every Step of the Way Attenuation Markers in the Vaccine Lineage A multicenter non-randomized, 704 uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment 705 with favipiravir for patients with severe fever with thrombocytopenia syndrome In vitro evolution of Remdesivir resistance 710 reveals genome plasticity of SARS-CoV-2 Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase 714 by remdesivir reveals a second mechanism of action Molecular Mechanism of Arenavirus Assembly and Budding Identification of potential 722 novel hosts and the risk of infection of lymphocytic choriomeningitis virus in humans in 723 Gérard, 727 M., n.d. Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and 728 Number 7-July 2020 -Emerging Infectious Diseases 729 journal -CDC Quasispecies diversity 731 determines pathogenesis through cooperative interactions in a viral population Vitro Assessment of 734 Combinations of Enterovirus Inhibitors against Enterovirus 71. Antimicrob. Agents 735 Chemother Therapeutic 737 Effect of the Antiviral Agent Ribavirin in Junin Virus Infection of Primates Low-dose ribavirin 741 potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses Human BST-2/tetherin inhibits Junin virus 744 release from host cells and its inhibition is partially counteracted by viral nucleoprotein Defective Interfering Particles of Negative-Strand RNA Viruses